DANA MARIA ALBULESCU, MARA CARSOTE, NINA IONOVICI, ADINA GHEMIGIAN, MIHAELA POPESCU, MIHAELA JANA TUCULINA, IONELA TEODORA DASCALU, SMARANDA ADELINA PREDA, TIBERIU TIRCA, MIHAI SEVER PETRESCU, MARILENA BATAIOSU, EDWIN SEVER BECHIR 5-HYDROXYTRIPTAMINE AND SKELETON INFLUENCE CLINICAL STUDY 5-hydroxytryptamine (5-HT) dually influences skeleton status through positive, indirect central effect and negative, direct, gut-associated impact. Circulating form is usually tested via venous blood sample. A limited number of clinical studies are published on this specific topic. We introduce a cross-sectional study on menopausal women with normal (N=29) and low bone mineral density (N=32) based on lumbar Dual-Energy X-Ray Absorptiometry (DXA) to whom serum serotonin was assessed and found no correlation with bone loss. This aspect confirms conflicting published data regarding the relationship between circulating levels and fracture risk assessment.